Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Echographic measurements, Blood samples · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Echographic measurements | PROCEDURE | - |
| Blood samples | PROCEDURE | - |
Inclusion Criteria: * Postmenopausal women defined as having Age =\< 70 years with documented menopause * Fasting LDL cholesterol 130 mg/ dl (3.37 mmol/l)and =\< 190 mg/ dl (4.92 mmol/l) after 6 weeks of diet * Triglycerides =\< 4 g/l(4.52 mmol/l) * Informed, written consent Exclusion Criteria: *...
Echographic measurements, Blood samples is an investigational diagnostic approach being studied in hypercholesterolaemia, a condition of high cholesterol. It was evaluated in a Phase 3 clinical trial involving post-menopausal women with the condition. The study is completed, and the drug remains in clinical development.
Echographic measurements, Blood samples is developed by Pfizer, Inc., a company listed on the New York Stock Exchange under the ticker PFE. The developer is responsible for the clinical development of this investigational product for hypercholesterolaemia.
Echographic measurements, Blood samples is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, double-blind study. The product is investigational and has not been reported as approved for any use.
Echographic measurements, Blood samples has one completed clinical trial, NCT00163163, titled 'Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women'. This Phase 3 study enrolled 400 female participants aged 18 years and older with hypercholesterolaemia, conducted in Belgium, France, and the Netherlands.
Echographic measurements, Blood samples is not stated to be the same as atorvastatin. The clinical trial NCT00163163 is titled 'Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women', but the drug name refers to the diagnostic measurements taken during the study, not the treatment being tested.